189 related articles for article (PubMed ID: 23807569)
1. Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin.
Sommer WH; Ceelen F; García-Albéniz X; Paprottka PM; Auernhammer CJ; Armbruster M; Nikolaou K; Haug AR; Reiser MF; Theisen D
Eur Radiol; 2013 Nov; 23(11):3094-103. PubMed ID: 23807569
[TBL] [Abstract][Full Text] [Related]
2. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
3. Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases?
Ceelen F; Theisen D; de Albéniz XG; Auernhammer CJ; Haug AR; D'Anastasi M; Paprottka PM; Rist C; Reiser MF; Sommer WH
J Magn Reson Imaging; 2015 Feb; 41(2):361-8. PubMed ID: 24446275
[TBL] [Abstract][Full Text] [Related]
4. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
6. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
7. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
[TBL] [Abstract][Full Text] [Related]
8. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
[TBL] [Abstract][Full Text] [Related]
9. Hepatic neuroendocrine metastases: chemo- or bland embolization?
Pitt SC; Knuth J; Keily JM; McDermott JC; Weber SM; Chen H; Rilling WS; Quebbeman EJ; Agarwal DM; Pitt HA
J Gastrointest Surg; 2008 Nov; 12(11):1951-60. PubMed ID: 18709512
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Zarghampour M; Khoshpouri P; Ameli S; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Oct; 29(10):5160-5171. PubMed ID: 30877462
[TBL] [Abstract][Full Text] [Related]
11. Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.
Benson AB; Geschwind JF; Mulcahy MF; Rilling W; Siskin G; Wiseman G; Cunningham J; Houghton B; Ross M; Memon K; Andrews J; Fleming CJ; Herman J; Nimeiri H; Lewandowski RJ; Salem R
Eur J Cancer; 2013 Oct; 49(15):3122-30. PubMed ID: 23777743
[TBL] [Abstract][Full Text] [Related]
12. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
[TBL] [Abstract][Full Text] [Related]
13. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization.
Liapi E; Geschwind JF; Vossen JA; Buijs M; Georgiades CS; Bluemke DA; Kamel IR
AJR Am J Roentgenol; 2008 Jan; 190(1):67-73. PubMed ID: 18094295
[TBL] [Abstract][Full Text] [Related]
14. [Arterial embolization of hepatic metastases from neuroendocrine tumors].
Libicher M; Bovenschulte H
Radiologe; 2009 Mar; 49(3):233-41. PubMed ID: 19183927
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis.
Shaheen M; Hassanain M; Aljiffry M; Cabrera T; Chaudhury P; Simoneau E; Kongkaewpaisarn N; Salman A; Rivera J; Jamal M; Lisbona R; Khankan A; Valenti D; Metrakos P
HPB (Oxford); 2012 Jan; 14(1):60-6. PubMed ID: 22151453
[TBL] [Abstract][Full Text] [Related]
16. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.
Dong XD; Carr BI
Med Oncol; 2011 Dec; 28 Suppl 1():S286-90. PubMed ID: 21107755
[TBL] [Abstract][Full Text] [Related]
17. Everolimus after hepatic arterial embolisation therapy of metastases from gastrointestinal neuroendocrine tumours: The FFCD 1104-EVACEL-GTE phase II study.
Walter T; Lepage C; Coriat R; Barbier E; Cadiot G; Caroli-Bosc FX; Aparicio T; Bouhier-Leporrier K; Hentic-Dhome O; Gay F; Dupont-Gossart AC; Duluc M; Lepere C; Lecomte T; Smith D; Petorin C; Di-Fiore F; Ghiringhelli F; Legoux JL; Guimbaud R; Baudin E; Lombard-Bohas C; de Baère T;
Eur J Cancer; 2019 Dec; 123():92-100. PubMed ID: 31678771
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
[TBL] [Abstract][Full Text] [Related]
19. Experience in primary hepatic neuroendocrine tumor.
Jia C; Zhang Y; Xu J; Sun K
Turk J Gastroenterol; 2012; 23(5):546-51. PubMed ID: 23161300
[TBL] [Abstract][Full Text] [Related]
20. Hepatic surgery for metastases from neuroendocrine tumors.
Sarmiento JM; Que FG
Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
